TITLE PAGE Study Title: STRIVE: A Multicenter Phase 2, Randomized, Double Blind, Efficacy and Safety Study of Enzalutamide vs Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy Investigational Product: Enzalutamide/PF-04998299 Indication: Prostate Cancer Sponsor: Medivation, Inc., a wholly owned subsidiary of Pfizer Inc 525 Market Street, 36th Floor San Francisco, CA 94105 Co-Sponsor: Astellas Pharma 1 Astellas Way Northbrook, IL 60062 Medivation, Inc. (Medivation), a wholly owned subsidiary of Pfizer, Inc. and Astellas Pharma Global Development, Inc. (Astellas) are in a partnership to codevelop enzalutamide for the treatment of cancer Protocol Number: MDV3100-09 (C3431014) Phase of Development: Phase 2 Study Initiation Date: First Subject First Visit: 07 August 2012 Primary Completion Date: 09 February 2015 Study Completion Date: Last Subject Last Visit: 17 January 2018 Sponsor’s Signatories: MD, PhD Report Date: 26 October 2018 Previous Report Date(s): Not Applicable Investigators: See below UNITED UNITED STATES STATES GCP STATEMENT This study was conducted in compliance with Good Clinical Practice (GCP) guidelines and, where applicable, local country regulations relevant to the use of new therapeutic agents in the country/countries of conduct, including the archiving of essential documents. TITLE PAGE .............................................................................................................................1 LIST OF TABLES .....................................................................................................................5 LIST OF FIGURES ...................................................................................................................6 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ..............................................9 ETHICS....................................................................................................................................10 Institutional Review Board.............................................................................................10 Ethical Conduct of the Study .........................................................................................10 INTRODUCTION ...................................................................................................................10 STUDY OBJECTIVES............................................................................................................10 INVESTIGATIONAL PLAN ..................................................................................................11 Study Design ..................................................................................................................11 Selection of Study Population ........................................................................................12 Inclusion and Exclusion Criteria ..........................................................................12 DB Phase Eligibility Criteria..................................................................12 OLE Eligibility Criteria..........................................................................12 Treatments ......................................................................................................................13 Dose Modification ................................................................................................13 Criteria for Discontinuation ..................................................................................13 Prior and Concomitant Medication.......................................................................14 Efficacy, Pharmacokinetic, Pharmacodynamic, Safety and/or Other Evaluations ........14 Efficacy Evaluations .............................................................................................14 Pharmacokinetic and Pharmacodynamic Evaluations and/or other Evaluations.......................................................................................................14 Safety Evaluations ................................................................................................14 Statistical Methods Planned in the Protocol and Determination of Sample Size...........15 Safety Assessment ................................................................................................15 Changes From the Planned Analysis..............................................................................15 RESULTS ................................................................................................................................15 Subject Disposition and Data Sets Analyzed .................................................................15 Demography ...................................................................................................................15 Concomitant Medication ................................................................................................15 Dose Modification ................................................................................................16 Efficacy Results..............................................................................................................16 Pharmacokinetic, Pharmacodynamic, and/or Other Results ..........................................17 Safety Results .................................................................................................................17 Commonly Reported TEAEs .................................................................17 Grade 3 or Higher TEAEs ......................................................................21 Study Drug-Related TEAEs ...................................................................21 Death ......................................................................................................21 Serious TEAEs......................................................................................................23 TEAEs of Interest .................................................................................................25 Other Significant TEAEs ......................................................................................25 Other Safety Data .................................................................................................26 Hematological Parameters......................................................................26 Serum Chemistry....................................................................................26 Vital Signs ..............................................................................................26 Death Narratives ...................................................................................................26 Other Serious Adverse Event Narratives ..............................................................26 Other Significant Adverse Events Narratives.......................................................27 CONCLUSION........................................................................................................................27 SUMMARY TABLES.............................................................................................................28 REFERENCES (NOT APPLICABLE) ...................................................................................31 ERRATA LIST OF TABLES Table 1. Treatment Compliance and Exposure - Safety Population...................................16 Table 2. Overall Summary of TEAEs - Safety Population.................................................17 Table 3. Frequently Reported (≥5%) TEAEs by SOC and PT - Safety Population ...........19 Table 4. Summary of TEAEs That Led to Death by PT – Safety Population ....................22 Table 5. Summary of All Deaths - ITT Population ............................................................23 Table 6. Frequently Reported (≥2%) Summary of Serious TEAEs by SOC - Safety Population .............................................................................................................24 Figure 1. Overview of Study Design....................................................................................11 16.1 Study Information 16.1.1 Final Protocol 16.1.3 Independent Ethics Committee (IEC) or Institutional Review Board (IRB) and Sample Standard Subject Information Sheet and Informed Consent Document (ICD) 16.1.3.1 List of IECs or IRB 16.1.4 Investigators and Corresponding Ethics Committees (IEC) or Institutional Review Boards (IRB), and Curriculum Vitae (CV) 16.1.4.1 Investigators and Corresponding Ethics Committees (IEC) or Institutional Review Boards (IRB), and Curriculum Vitae (CV) 16.1.4.2 Study Administrative Structure 16.1.5 Signatures of Principal or Coordinating Investigator(s) or Sponsor's Responsible Medical Officer, Depending on The Regulatory Authority's Requirement 16.1.5.1 Sponsor 16.1.5.2 CSR Investigator Declaration 16.1.6 Listing of Subjects Receiving Test Drug(S)/Investigational Product(S) From Specific Batches, Where More Than One Batch Was Used 16.1.7 Randomization Scheme and Codes (Subject Identification and Treatment Assigned) 16.1.7.1 Description of Randomization 16.1.9 Documentation of Statistical Methods 16.1.9.1 Statistical Analysis Plan 16.1.9.2 Statistical Output (Not Applicable) 16.2 Subject Data Listings 16.2.1 Discontinued Subjects (Not Applicable) 16.2.2 Protocol Deviations 16.2.3 Subjects Excluded From the Efficacy Analysis (Not Applicable) 16.2.4 Demographic Data Listing 16.2.4.5 Concomitant Medications (Safety Population) 16.2.5 Compliance and/or Drug Concentration Data Listing 16.2.5.1 Treatment Compliance and Exposure (Safety Population) 16.2.7 Adverse Event Listing by Subject Listing 16.2.7.1 Treatment-Emergent Adverse Events (Safety Population) Listing 16.2.7.2 Grade 3 or Higher Treatment-Emergent Adverse Events (Safety Population) Listing 16.2.7.3 All Deaths (ITT Population) Listing 16.2.7.4 Serious Treatment-Emergent Adverse Events (Safety Population) 16.2.8 Listing of Individual Laboratory Measurements by Subject Listing 16.2.8.1.1 Patients with Grade 3 or 4 Laboratory Values – Hematology (Safety Population) Listing 16.2.8.2.1 Patients with Grade 3 or 4 Laboratory Values – Chemistry (Safety Population) Listing 16.2.8.3 Vital Signs (Safety Population) 16.3 Case Report Forms (CRFs) All Case Report Forms (CRFs) or Data Collection Tools agreed upon with regulatory agencies to be submitted will be provided in Module 5 of the Common Technical Document for New Drug Applications (United States of America) and in Section 5 of New Drug Submissions (Canada), and will be available upon request for Marketing Authorization Applications (Europe) and Japanese New Drug Applications. 16.3.1 CRFs For Deaths, Other Serious Adverse Events, and Withdrawals for Adverse Events 16.3.2 Other CRFs Submitted 16.4 Individual Subject Data Listings Abbreviation Definition AEs adverse events ALT alanine aminotransferase ANC absolute neutrophil count AST aspartate aminotransferase CRF case report form CSR clinical study report DB Double-blind ECOG Eastern Cooperative Oncology Group FACT-P functional assessment on cancer therapy-prostate GCP Good Clinical Practice GnRH gonadotropin-releasing hormone IRB Institutional Review Board ITT intent-to-treat LFT liver function test M0 non-metastatic M1 metastatic N0 no regional nodal metastasis N1 regional nodal metastasis MedDRA Medical Dictionary for Regulatory Activities OL open-label OLE open-label extension PFS progression free survival PSA prostate specific antigen PT preferred term rPFS radiographic progression-free survival SAE serious adverse event SD standard deviation SOC system organ class TEAEs treatment-emergent adverse events ULN upper limit of normal Institutional Review Board The final protocol and any amendments (Section 16.1.1) were reviewed and approved by the Institutional Review Board (IRB) at each of the investigational centers participating in the study. The IRBs are listed in Section 16.1.3. Ethical Conduct of the Study This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial participants. INTRODUCTION Please refer to the primary clinical study report (CSR) dated 14 Aug 2015 for background information. The purpose of this study was to evaluate the effects of enzalutamide versus bicalutamide on progression free survival (PFS), prostate specific antigen (PSA) progression, PSA response, radiographic progression-free survival (rPFS), quality of life, and safety in patients with non-metastatic (M0) or metastatic (M1) prostate cancer after failure of primary androgen deprivation therapy. The contents of this report are intended to supplement to the primary CSR and present the results of the final assessment of safety performed for patients enrolled in this Phase 2, randomized, double-blind (DB), multicenter study. STUDY OBJECTIVES The objectives of this study for the DB period were previously met and summarized in the primary CSR (14 Aug 2015) for Protocol MDV3100-09 (C3431014). Data pertaining to safety were collected during the open-label extension (OLE) phase of the study and are presented in this report, along with cumulative safety data. Open Label Study Objectives:  To offer open label enzalutamide treatment after study unblinding to patients receiving enzalutamide or bicalutamide at the time of unblinding and qualifying patients randomized to bicalutamide who discontinued during the DB period prior to unblinding;  To obtain additional safety data on enzalutamide use. Study Design This study was a multicenter Phase 2, randomized, DB study to evaluate the efficacy and safety of enzalutamide (160 mg/day) versus bicalutamide (50 mg/day) in patients with recurrent prostate cancer who have serologic and/or radiographic disease progression despite primary androgen deprivation therapy. In the DB phase, approximately 400 patients were centrally randomized in 1:1 ratio to enzalutamide (160 mg/day) or bicalutamide (50 mg/day). Randomization was stratified by disease stage (M0/N0 [no distant metastasis and no regional nodal metastasis], M0/N1 [no distant metastasis but presence of regional nodal metastasis, defined as involvement of nodes below the aortic bifurcation], or M1 [presence of distant metastasis, which could have included nodal involvement above the aortic bifurcation]). As the primary objective of the study was met demonstrating benefit in rPFS with enzalutamide compared to bicalutamide, patients receiving enzalutamide or bicalutamide at the time of unblinding and qualifying patients randomized to bicalutamide who discontinued prior to unblinding were offered the opportunity to receive open-label (OL) enzalutamide treatment after the DB phase. The data collected during the OLE was limited to safety assessments. Patients were to have study visits on OL Day 1 (Week 1), at Week 5 (telephone call), Week 17, and every 16 weeks thereafter. Patients were to take enzalutamide as four 40-mg soft gelatin capsules (160 mg/day) by mouth once daily with or without food (Figure 1). Patients were to have safety follow-up approximately 30 days after the last dose or before initiating a new antineoplastic treatment, whichever occurred first. Every reasonable effort was to be made to contact patients apparently lost to follow-up to complete study-related assessments, record outstanding data, and retrieve study drug. These efforts were documented in the patient’s source documents. Safety and tolerability were evaluated by assessment of adverse events (AEs), physical examinations, vital signs, and laboratory evaluations during the treatment period through 30 days after the last dose of study drug or before initiation of cytotoxic or investigational therapy, whichever occurred first. Figure 1. Overview of Study Design Receiving Discontinued Enzalutamide Randomized Bicalutamide or Bicalutamide Patients randomized to enzalutamide who Double-Blind or before at time of discontinued before study unblinding are Treatment unblinding unblinding ineligible for open-label treatment Period Treatment unblinded Informed consent Open-Label End of Safety Treatment Screening Enzalutamide Treatment Follow-Up Period OL OL OL Approximately day 1 week 5 week 17 30 days after phone call repeating last dose q16 weeks Abbreviations: OL = open-label; q16 weeks = every 16 weeks. Selection of Study Population Inclusion and Exclusion Criteria DB Phase Eligibility Criteria Men aged ≥18 years with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, small cell, or ductal features; ongoing androgen deprivation therapy for prostate cancer with a gonadotropin-releasing hormone (GnRH) analogue at a stable dose and scheduled as of 4 weeks immediately before Day 1, or bilateral orchiectomy (ie, medical or surgical castration) were enrolled in this study. Patients who had prior intermittent therapy with a GnRH analogue; a bilateral orchiectomy; serum testosterone level ≤50 ng/dL (1.73 nmol/L) at Screening were eligible. Patients were required to have progressive disease by PSA or imaging. Patients with asymptomatic or mildly symptomatic from prostate cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening and Day 1, and estimated life expectancy of ≥12 months were included. Patients with severe concurrent disease, infection, or comorbidity; known or suspected brain metastasis or active leptomeningeal disease; another invasive cancer within 5 years of randomization were not enrolled in this study. OLE Eligibility Criteria All eligible patients were to meet the inclusion criteria for the OLE; these included patients who were randomized in the DB to enzalutamide and still receiving enzalutamide at the time of study unblinding, as well as patients randomized in the DB to bicalutamide who were still receiving bicalutamide at the time of study unblinding or who had discontinued bicalutamide before study unblinding. Patients also must have been willing to maintain androgen deprivation therapy with a GnRH agonist/antagonist or have had a bilateral orchiectomy. Eligible patients were able to swallow enzalutamide capsules whole and able to comply with study requirements throughout the study. See protocol Supplement 1 (primary CSR Section 16.1.1) for complete OLE inclusion criteria. For the OLE, exclusion criteria only applied to patients who received bicalutamide as randomized treatment in the DB and discontinued prior to unblinding. These patients were to be excluded if they were taking or had taken commercially available enzalutamide (Xtandi) prior to participation in the OLE, had withdrawn consent to participate in the study during the DB, or had any clinically significant condition that may have interfered with study participation in the opinion of the investigator or medical monitor. Patients were also excluded from the study if they met any of the laboratory values (liver function tests [LFTs], creatinine, and absolute neutrophils) or vital sign values pre-specified in the protocol, or if they had taken cytotoxic chemotherapy or investigational therapy within 4 weeks prior to enrollment in the OLE. See protocol Supplement 1 (primary CSR Section 16.1.1) for complete OLE exclusion criteria. In the DB phase, patients who were randomized to the enzalutamide treatment arm had taken 160 mg (4 capsules) of active enzalutamide and 1 bicalutamide placebo capsule orally once daily. Patients who were randomized to the bicalutamide treatment arm had taken 50 mg (1 capsule) of active bicalutamide and 4 enzalutamide placebo capsules orally once daily. In the OLE phase, all patients were to self-administer four 40-mg soft gelatin enzalutamide capsules (160 mg/day) by mouth once daily with or without food, unless they were receiving a reduced dose during the DB phase (if so, treatment was to continue at the reduced dose). OL enzalutamide administration was to continue as long as the treatment was determined to be beneficial in the judgment of the investigator or until the development of any intolerable AEs. Study drug lot numbers for OL enzalutamide are presented in Section 16.1.6. Dose Modification In the event of a Grade 3 or higher toxicity that could not be ameliorated by the use of adequate medical intervention, enzalutamide treatment could have been interrupted for 1 week. In consultation with the medical monitor, dosing could be restarted at the original dose (160 mg/day) or a reduced dose (120 or 80 mg/day) if the toxicity grade improved to a Grade 2 or lower severity. If enzalutamide was coadministered with a strong CYP2C8 inhibitor (ie, gemfibrozil), the dose of enzalutamide was to be reduced to 80 mg once daily. If coadministration of the strong CYP2C8 inhibitor was discontinued, the enzalutamide dose was to return to the dose used prior to initiation of the strong CYP2C8 inhibitor. In the event that a patient’s treatment was interrupted due to an AE and was then restarted, regularly scheduled study visits were to continue based on the patient’s Day 1 visit in the OLE. Criteria for Discontinuation Patients were to permanently discontinue from treatment with enzalutamide for the following reasons:  Intolerable AEs that could not be ameliorated by adequate medical intervention; or that in the opinion of the investigator or medical monitor could have led to undue risk if treatment with enzalutamide was continued.  Seizure or any condition that significantly may have predisposed the patient to seizure, including, but not limited to brain metastasis, cortically based stroke, or hemorrhage in the central nervous system.  Initiation of cytotoxic chemotherapy, investigational therapy, or another antiandrogen. alanine aminotransferase (ALT), or aspartate aminotransferase (AST) >5 × upper limit of normal (ULN); or absolute neutrophil count 750/L). Patients were also permanently discontinued from enzalutamide treatment for the following reasons:  Withdrawal of consent (patient decision any time for any reason). Patients may withdraw consent for further treatment.  Gross noncompliance with protocol procedures and study drug management.  Sponsor discontinuation of study. Prior and Concomitant Medication Medications taken within 4 weeks before OL Day 1 and any medications prescribed for chronic or intermittent use, or dose adjustments of these medications, was recorded on the case report forms (CRFs) and source documents. Concomitant medications included all vitamins, herbal remedies, and over-the-counter supplements and prescription medications. Concomitant medications were assessed at Screening and all clinic visits. If any medication was used due to an AE during the study, the AE was recorded on the AE CRF and in the patient’s source documents. Ongoing androgen deprivation therapy with a GnRH agonist/antagonist was required throughout the study to maintain castrate levels of testosterone for patients without a prior bilateral orchiectomy. The use of concurrent cytotoxic chemotherapy, investigational anticancer agents, or another antiandrogen (eg, bicalutamide, flutamide, nilutamide) was prohibited. However, initiation of bisphosphonates or denosumab for bone health was allowed, and standard of care supplementation with calcium and vitamin D was encouraged. Efficacy, Pharmacokinetic, Pharmacodynamic, Safety and/or Other Evaluations Efficacy Evaluations Please refer to the primary CSR dated 14 Aug 2015. Pharmacokinetic and Pharmacodynamic Evaluations and/or other Evaluations Please refer to the primary CSR dated 14 Aug 2015. Safety Evaluations The safety of enzalutamide was assessed every 16 weeks at regular study visits and at as needed unscheduled visits by the frequency of AEs, Grade 3 or higher AEs, serious adverse events (SAEs), AEs that were the primary reason for discontinuation of study drug, AEs associated with discontinuation of study drug, AEs events leading to dose interruption, dose reduction, and deaths, as well as the frequency of new clinically significant changes in vital signs and laboratory values. Safety Assessment All safety analyses were conducted using the safety population, defined as all patients who received any amount of enzalutamide. Safety was evaluated by the incidence of SAEs, incidence and severity of AEs, incidence of study drug discontinuation due to AEs, and incidence of new clinically-significant changes in clinical laboratory values and vital signs. All AEs were coded to preferred term (PT) and system organ class (SOC) using the Medical Dictionary for Regulatory Activities (MedDRA). Descriptive statistics were presented for the number and percentage of patients with AEs by MedDRA SOC and PT, relationship to study treatment, and severity. Changes From the Planned Analysis There were no changes to the planned analysis. RESULTS Subject Disposition and Data Sets Analyzed In the DB phase, there were 197 patients enrolled in the enzalutamide group and 198 patients in the bicalutamide group. After the DB phase, 93 patients from the enzalutamide group continued receiving enzalutamide in the open-label phase and 38 patients from the bicalutamide group were crossed over to enzalutamide treatment during the open-label phase, where 37 of these subjects received enzalutamide (Table 14.1.1 and Table 14.1.4). Demography Please refer to the primary CSR dated 14 Aug 2015. Concomitant Medication There were 183 (92.9%), 172 (86.9%), and 31 (83.8%) patients with at least 1 concomitant medication for the enzalutamide, bicalutamide, and crossover from bicalutamide to enzalutamide groups, respectively. The most common concomitant medications were analgesics (43.1%, 39.9%, and 43.2%, respectively), antibacterials for systemic use (38.1%, 34.3%, and 40.5%, respectively) and antithrombotic agents (35.0%, 19.2%, and 18.9%, respectively) Table 14.1.3. Protocol Deviations A listing of all protocol deviations is presented in Section 16.2.2. Extent of Exposure and Study Drug Extent of exposure and study drug compliance are presented for the safety population in Table 1. The overall reported compliance rate was similar between the enzalutamide (mean [standard deviation (SD)]; 94.1 [12.98]) and bicalutamide groups (97.3 [7.87]), and the majority of the patients had a compliance rate ≥80.0%. The compliance rate was lower in crossover from bicalutamide to enzalutamide group (72.3 [15.58]) and the majority had was the shortest of the treatment groups, as patients received this treatment in the DB only. Of these patients, those that went on to receive OL enzalutamide had a longer median duration of treatment (18.4 months) in the OLE. The median duration of treatment for those taking enzalutamide throughout the study was the longest (22.1 months), as the duration of treatment includes both the DB and OLE phases (Table 14.1.1). Table 1. Treatment Compliance and Exposure - Safety Population Bicalutamide Patients Crossover to Enzalutamide 160 mg Bicalutamide Enzalutamide 160 mg Interpretation (N = 197) (N = 198) (N = 37) Treatment duration (months)1 n 197 198 37 Mean (SD) 26.1 (18.06) 10.9 (7.60) 15.8 (9.80) Number of capsules taken2 n 197 198 37 Mean (SD) 3508.9 (2347.35) 1604.9 (1111.56) 1709.9 (1112.45) Compliance3n 197 198 37 Mean (SD) 94.1 (12.98) 97.3 (7.87) 72.3 (15.58) Compliance category3 <20% 1 (0.5%) 0 (0.0%) 1 (2.7%) ≥20% to <40% 0 (0.0%) 0 (0.0%) 0 (0.0%) ≥40% to <60% 0 (0.0%) 1 (0.5%) 3 (8.1%) ≥60% to <80% 5 (2.5%) 7 (3.5%) 29 (78.4%) ≥80% to ≤100% 173 (87.8%) 169 (85.4%) 4 (10.8%) >100% to <105% 13 (6.6%) 18 (9.1%) 0 (0.0%) ≥105% 5 (2.5%) 3 (1.5%) 0 (0.0%) Source: Table 14.1.1 Abbreviation: N = number of patients; SD = standard deviation. 1 Treatment duration was calculated as (last dose date of study drug - first dose date of study drug + 1)/30.4375. 2 Total number of capsules taken was calculated as number of capsules dispensed at all study visits - number of capsules indicated as returned. 3 Overall compliance rate was calculated as (number of capsules taken during the study/expected number of capsules during the study) × 100. Four (4) capsules were taken per day according to the protocol. Dose Modification The dose modifications are presented in Table 14.1.2. No dose modifications were reported for 77.2% of the enzalutamide (DB and OLE) group, 86.4% of patients taking bicalutamide in the DB, or 62.2% of the patients that crossed over to enzalutamide in the OLE; the rest of the subjects reported at least 1 dose modification. The primary cause of dose interruptions and dose reductions was AEs for all treatment groups. Efficacy Results Please refer to the primary CSR dated 14 Aug 2015. Please refer to the primary CSR dated 14 Aug 2015. Safety Results The overall summary of treatment emergent adverse events (TEAEs) is presented in Table 2. Although, the median duration of treatment was substantially shorter in patients taking bicalutamide in the DB period, similar percentages of patients reported at least 1 TEAE in each group (enzalutamide [DB/OLE]: 96.4% [190 patients]; bicalutamide [DB only]: 90.4% [179 patients]; and enzalutamide [OLE only]: 97.3% [36 patients]). The proportion of patients who reported TEAEs that were Grade 3 or higher was 45.7%, 38.4%, and 54.1% for the enzalutamide (DB/OLE), bicalutamide (DB only), and crossover from bicalutamide to enzalutamide groups (OLE only), respectively. Overall, the incidence of TEAEs reported in each treatment group was comparable (Table 14.3.1.1.1). Variations in incidence may be accounted for by differences in sample size (for example the number of patients crossing over to open-label enzalutamide is relatively low), disease burden at the time of crossover, and overall time on study. Table 2. Overall Summary of TEAEs - Safety Population Bicalutamide Patients Enzalutamide Crossover to 160 mg Bicalutamide Enzalutamide 160 mg (N = 197) (N = 198) (N = 37) Number of Patients Reporting at Least 1 TEAE n (%) n (%) n (%) TEAE 190 (96.4%) 179 (90.4%) 36 (97.3%) TEAE that was primary reason for study drug discontinuation1 21 (10.7%) 13 (6.6%) 8 (21.6%) TEAE leading to study drug discontinuation2 32 (16.2%) 26 (13.1%) 9 (24.3%) TEAE leading to dose interruption of study drug 46 (23.4%) 28 (14.1%) 10 (27.0%) TEAE leading to dose reduction of study drug 16 (8.1%) 3 (1.5%) 8 (21.6%) TEAE leading to death 9 (4.6%) 6 (3.0%) 3 (8.1%) Serious TEAE 76 (38.6%) 60 (30.3%) 16 (43.2%) Grade 3 or higher TEAE 90 (45.7%) 76 (38.4%) 20 (54.1%) TEAE related to study drug 131 (66.5%) 106 (53.5%) 26 (70.3%) Grade 3 or higher TEAE related to study drug 30 (15.2%) 14 (7.1%) 7 (18.9%) Serious TEAE related to study drug 15 (7.6%) 7 (3.5%) 1 (2.7%) Source: Table 14.3.1.1.1 Abbreviations: AE = adverse event; CRF = case report form; N = number of patients; TEAE = treatment-emergent adverse event. Subject had the reason for treatment discontinuation listed as an AE; however, since the outcome of the AE was fatal, the reason for treatment discontinuation should have been revised to death (see Errata). 1 TEAE identified as primary reason for study drug discontinuation was from treatment discontinuation CRF. 2 TEAE led to study drug discontinuation was from AE CRF and includes TEAEs with action taken of permanent discontinuation. Commonly Reported TEAEs A summary of TEAEs that occurred in ≥5% of patients in any treatment group by SOC and PT for the safety population is presented in Table 3. enzalutamide [DB/OLE]), bicalutamide (DB only), and crossover from bicalutamide to enzalutamide groups (OLE only), respectively; arthralgia (23.4%, 14.6%, and 13.5%, respectively), fall (21.3%, 9.6%, and 21.6%, respectively); back pain (20.8%, 17.2%, and 8.1%, respectively), and nausea (19.3%, 16.2%, and 24.3%, respectively). TEAEs were summarized by SOC and PT in Table 14.3.1.2.1 and Table 14.3.1.2.2 and a list of TEAEs is presented by-patient in Listing 16.2.7.1. Table 3. Frequently Reported (≥5%) TEAEs by SOC and PT - Safety Population Enzalutamide 160 mg Bicalutamide Bicalutamide (N = 197) (N = 198) Patients Crossover to Enzalutamide 160 mg (N = 37) SOC Grade All Grade All Grade All PT 3/4/5 3/4/5 3/4/5 Blood and lymphatic system disordersAnaemia 10 (5.1%) 24 (12.2%) 10 (5.1%) 21 (10.6%) 3 (8.1%) 4 (10.8%) Cardiac disorders Cardiac failure congestive 6 (3.0%) 7 (3.6%) 2 (1.0%) 5 (2.5%) 2 (5.4%) 4 (10.8%) Atrial fibrillation 4 (2.0%) 6 (3.0%) 1 (0.5%) 6 (3.0%) 0 (0.0%) 3 (8.1.%) Gastrointestinal disorders Nausea 1 (0.5%) 38 (19.3%) 1 (0.5%) 32 (16.2%) 0 (0.0%) 9 (24.3%) Constipation 0 (0.0%) 29 (14.7%) 1 (0.5%) 33 (16.7%) 0 (0.0%) 6 (16.2%) Diarrhoea 3 (1.5%) 27 (13.7%) 2 (1.0%) 29 (14.6%) 0 (0.0%) 9 (24.3%) Abdominal pain 0 (0.0%) 15 (7.6%) 1 (0.5%) 7 (3.5%) 1 (2.7%) 2 (5.4%) Vomiting 1 (0.5%) 12 (6.1%) 0 (0.0%) 17 (8.6%) 0 (0.0%) 3 (8.1%) Gastrooesophageal reflux 0 (0.0%) 10 (5.1%) 0 (0.0%) 2 (1.0%) 0 (0.0%) 6 (16.2%) disease General disorders and administration site conditions 10 Fatigue 10 (5.1%) 83 (42.1%) 5 (2.5%) 57 (28.8%) 2 (5.4%) (27.0%) Asthenia 4 (2.0%) 17 (8.6%) 3 (1.5%) 6 (3.0%) 0 (0.0%) 2 (5.4%) Oedema peripheral 0 (0.0%) 17 (8.6%) 0 (0.0%) 10 (5.1%) 0 (0.0%) 1 (2.7%) Pyrexia 0 (0.0%) 5 (2.5%) 1 (0.5%) 13 (6.6%) 0 (0.0%) 1 (2.7%) Infections and infestations Urinary tract infection 4 (2.0%) 16 (8.1%) 7 (3.5%) 23 (11.6%) 1 (2.7%) 7 (18.9%) Pneumonia 5 (2.5%) 10 (5.1%) 4 (2.0%) 10 (5.1%) 0 (0.0%) 1 (2.7%) Injury, poisoning and procedural complications Fall 6 (3.0%) 42 (21.3%) 3 (1.5%) 19 (9.6%) 1 (2.7%) 8 (21.6%) Laceration 0 (0.0%) 10 (5.1%) 0 (0.0%) 3 (1.5%) 0 (0.0%) 0 (0.0%) Cystitis radiation 0 (0.0%) 1 (0.5%) 0 (0.0%) 1 (0.5%) 2 (5.4%) 2 (5.4%) Procedural pain 0 (0.0%) 1 (0.5%) 1 (0.5%) 4 (2.0%) 0 (0.0%) 2 (5.4%) InvestigationsWeight decreased 0 (0.0%) 16 (8.1%) 0 (0.0%) 13 (6.6%) 0 (0.0%) 3 (8.1%) Blood pressure increased 2 (1.0%) 3 (1.5%) 0 (0.0%) 1 (0.5%) 0 (0.0%) 2 (5.4%) Metabolism and nutrition disordersDecreased appetite 0 (0.0%) 28 (14.2%) 4 (2.0%) 17 (8.6%) 0 (0.0%) 6 (16.2%) Dehydration 4 (2.0%) 15 (7.6%) 1 (0.5%) 7 (3.5%) 1 (2.7%) 2 (5.4%) Hyperglycaemia 3 (1.5%) 13 (6.6%) 2 (1.0%) 14 (7.1%) 1 (2.7%) 2 (5.4%) Hypokalaemia 3 (1.5%) 13 (6.6%) 4 (2.0%) 11 (5.6%) 0 (0.0%) 2 (5.4%) Hyponatraemia 3 (1.5%) 10 (5.1%) 2 (1.0%) 4 (2.0%) 0 (0.0%) 2 (5.4%) Musculoskeletal and connective tissue disorders Arthralgia 5 (2.5%) 46 (23.4%) 2 (1.0%) 29 (14.6%) 0 (0.0%) 5 (13.5%) Back pain 4 (2.0%) 41 (20.8%) 2 (1.0%) 34 (17.2%) 0 (0.0%) 3 (8.1%) Pain in extremity 1 (0.5%) 23 (11.7%) 0 (0.0%) 10 (5.1%) 0 (0.0%) 1 (2.7%) Table 3. Frequently Reported (≥5%) TEAEs by SOC and PT - Safety Population Enzalutamide 160 mg Bicalutamide Bicalutamide (N = 197) (N = 198) Patients Crossover to Enzalutamide 160 mg (N = 37) SOC Grade All Grade All Grade All PT 3/4/5 3/4/5 3/4/5 Musculoskeletal pain 2 (1.0%) 18 (9.1%) 0 (0.0%) 11 (5.6%) 0 (0.0%) 2 (5.4%) Muscular weakness 2 (1.0%) 15 (7.6%) 0 (0.0%) 6 (3.0%) 0 (0.0%) 1 (2.7%) Musculoskeletal chest pain 0 (0.0%) 13 (6.6%) 0 (0.0%) 4 (2.0%) 0 (0.0%) 2 (5.4%) Myalgia 0 (0.0%) 10 (5.1%) 0 (0.0%) 5 (2.5%) 0 (0.0%) 1 (2.7%) Bone pain 1 (0.5%) 6 (3.0%) 0 (0.0%) 2 (1.0%) 0 (0.0%) 2 (5.4%) Nervous system disorders Dizziness 1 (0.5%) 27 (13.7%) 1 (0.5%) 15 (7.6%) 1 (2.7%) 6 (16.2%) Syncope 7 (3.6%) 10 (5.1%) 5 (2.5%) 5 (2.5%) 1 (2.7%) 2 (5.4%) Haemorrhagic stroke 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (5.4%) 2 (5.4%) Psychiatric disorders Insomnia 0 (0.0%) 22 (11.2%) 0 (0.0%) 9 (4.5%) 0 (0.0%) 2 (5.4%) Depression 0 (0.0%) 15 (7.6%) 0 (0.0%) 8 (4.0%) 0 (0.0%) 2 (5.4%) Anxiety 0 (0.0%) 13 (6.6%) 1 (0.5%) 3 (1.5%) 0 (0.0%) 0 (0.0%) Renal and urinary disorders Haematuria 7 (3.6%) 18 (9.1%) 4 (2.0%) 14 (7.1%) 1 (2.7%) 3 (8.1%) Pollakiuria 0 (0.0%) 11 (5.6%) 0 (0.0%) 7 (3.5%) 0 (0.0%) 0 (0.0%) Renal failure acute 3 (1.5%) 8 (4.1%) 1 (0.5%) 12 (6.1%) 0 (0.0%) 1(2.7%) Respiratory, thoracic and mediastinal disorders Dyspnoea 1 (0.5%) 19 (9.6%) 2 (1.0%) 12 (6.1%) 0 (0.0%) 1(2.7%) Cough 0 (0.0%) 14 (7.1%) 0 (0.0%) 9 (4.5%) 0 (0.0%) 1(2.7%) Skin and subcutaneous tissue disordersRash 0 (0.0%) 12 (6.1%) 0 (0.0%) 9 (4.5%) 1 (2.7%) 3 (8.1%) Vascular disorders Hot flush 0 (0.0%) 34 (17.3%) 1 (0.5%) 20 (10.1%) 0 (0.0%) 2 (5.4%) Hypertension 13 (6.6%) 26 (13.2%) 3 (1.5%) 10 (5.1%) 2 (5.4%) 5 (13.5%) Hypotension 3 (1.5%) 6 (3.0%) 3 (1.5%) 6 (3.0%) 0 (0.0%) 4 (10.8%) Source: Table 14.3.1.2.1 Abbreviations: N = number of patients; NCI-CTCAE = National Cancer Institute - Common Terminology Criteria for Adverse Events; PT = preferred term; SOC = system organ class TEAE = treatment emergent adverse events. A summary of TEAEs by SOC, PT, and strongest relationship to study drug is presented in Table 14.3.1.2.3 and a summary of TEAEs by decreasing frequency is presented in Table 14.3.1.2.4. A summary of TEAEs by SOC and PT adjusting for length of treatment- emergent period (events per 100 patient-year of reporting) is presented in Table 14.3.1.2.5. A summary of TEAEs, Grade 3 or higher TEAEs, and serious TEAEs by treatment day of onset cut point (1 – 30 days, 1 - 180 days, 1 - 365 days, and total) is presented in Table 14.3.1.2.6 and Table 14.3.1.3.4, and Table 14.3.2.1.5, respectively. The SOCs with Grade 3 or higher TEAEs reported most frequently included cardiac disorders (8.6%, 4.0%, and 13.5% for the enzalutamide [DB/OLE], bicalutamide [DB only], and crossover from bicalutamide to enzalutamide groups [OLE only], respectively); gastrointestinal disorders (7.1%, 4.0%, and 10.8%, respectively); infections and infestations (7.6%, 9.6%, and 10.8%, respectively); vascular disorders (10.2%, 5.1%, and 8.1%, respectively); general disorders and administration site conditions (9.6%, 5.6%, and 5.4%, respectively); and musculoskeletal and connective tissue disorders (9.6%, 3.0%, and 2.7%, respectively). Individual PTs for Grade 3 or higher TEAEs that were reported most frequently included hypertension (6.6%, 1.5%, and 5.4% for the enzalutamide [DB/OLE], bicalutamide [DB only], and crossover from bicalutamide to enzalutamide groups [OLE only], respectively), anaemia (5.1%, 5.1%, and 8.1%, respectively), fatigue (5.1%, 2.5%, and 5.4%, respectively), cardiac failure congestive (3.0%, 1.0%, and 5.4%, respectively), and cystitis radiation and haemorrhagic stroke from the crossover from bicalutamide to enzalutamide group only (both 5.4%) (Table 14.3.1.3.4). Grade 3 or higher TEAEs are summarized by SOC and PT in Table 14.3.1.3.1 and Table 14.3.1.3.2 and Grade 3 or higher TEAEs by-patient in Listing 16.2.7.2. Grade 3 or higher TEAEs are summarized by strongest relationship to study drug in Table 14.3.1.3.3. Study Drug-Related TEAEs The incidence of study-drug related TEAEs was 70.3% in the crossover from bicalutamide to enzalutamide group (OLE only), 66.5% in the enzalutamide group (DB/OLE), and 53.5% in the bicalutamide group (DB only). The incidence of TEAEs that were Grade 3 or higher and related to study drug was 18.9% in the crossover from bicalutamide to enzalutamide group (OLE only), 15.2% in the enzalutamide group (DB/OLE), and 7.1% in the bicalutamide group (DB only). Again, variations in incidence may be accounted for by differences in sample size, disease burden at the time of crossover, and overall time on study. TEAEs that were considered to be related to study drug are presented by SOC and PT in Table 14.3.1.4.1 and by maximum severity in Table 14.3.1.4.2. Death A summary of TEAEs that led to death (as indicated on the AE CRF) by PT is presented in Table 4. Overall, 4.6%, 3.0%, and 8.1% of subjects had at least 1 TEAE that led to death for the enzalutamide (DB/OLE), bicalutamide (DB only), and crossover from bicalutamide to enzalutamide groups (OLE only), respectively. Table 4. Summary of TEAEs That Led to Death by PT – Safety Population PT Enzalutamide 160 mg Bicalutamide Bicalutamide Patients (N = 197) (N = 198) Crossover to Enzalutamide 160 mg (N = 37) Number of patients reporting at least 9 (4.6%) 6 (3.0%) 3 (8.1%) 1 TEAE that led to death Cardio-respiratory arrest 1 (0.5%) 0 (0.0%) 0 (0.0%) Cardiac failure 0 (0.0%) 0 (0.0%) 1 (2.7%) Cardiac failure congestive 0 (0.0%) 0 (0.0%) 1 (2.7%) Duodenal perforation 1 (0.5%) 0 (0.0%) 0 (0.0%) Disease progression 1 (0.5%) 0 (0.0%) 0 (0.0%) General physical health deterioration 1 (0.5%) 1 (0.5%) 0 (0.0%) Hepatic failure 1 (0.5%) 0 (0.0%) 0 (0.0%) Pneumonia 1 (0.5%) 0 (0.0%) 0 (0.0%) Sepsis 1 (0.5%) 0 (0.0%) 0 (0.0%) Septic shock 0 (0.0%) 1 (0.5%) 0 (0.0%) Injury 0 (0.0%) 2 (1.0%) 0 (0.0%) Cholangiocarcinoma 1 (0.5%) 0 (0.0%) 0 (0.0%) Colon cancer metastatic 1 (0.5%) 0 (0.0%) 0 (0.0%) Metastasis to liver 1 (0.5%) 0 (0.0%) 0 (0.0%) Prostate cancer metastatic 1 (0.5%) 0 (0.0%) 0 (0.0%) Hemorrhage intracranial 0 (0.0%) 0 (0.0%) 1 (2.7%) Hypoglycaemic encephalopathy 0 (0.0%) 1 (0.5%) 0 (0.0%) Chronic obstructive pulmonary 0 (0.0%) 1 (0.5%) 0 (0.0%) disease Source: Table 14.3.2.2.1 Patients with multiple events for a given preferred term, system organ class, or overall are counted once only for each preferred term, system organ class, and overall, respectively and Death are as reported as fatal events on the AE page. Abbreviations: AE = adverse event; N = number of patients; PT = preferred term; TEAE = treatment emergent adverse event. Table 5. Summary of All Deaths - ITT Population Enzalutamide Bicalutamide Bicalutamide 160 mg (N = 198) Patients (N = 198) Crossover to Death Summary Enzalutamide 160 mg (N = 37) Total number of deaths 11 (5.6%) 6 (3.0%) 1 (2.7%)a Cause of death Disease progression 4 (2.0%) 1 (0.5%) 0 (0.0%) Adverse event 7 (3.5%) 5 (2.5%) 1 (2.7%) Deaths within 30 days after the first dose date of study 1 (0.5%) 0 (0.0%) 0 (0.0%) drugCause of death for all deaths within 30 days after the first dose date of study drug Adverse event 1 (0.5%) 0 (0.0%) 0 (0.0%) Cardio-respiratory arrest 1 (0.5%) 0 (0.0%) 0 (0.0%) Deaths within 30 days after the last dose date of study 7 (3.5%) 6 (3.0%) 1 (2.7%) drugCause of death for all deaths within 30 days after the last dose date of study drug Disease progression 2 (1.0%) 1 (0.5%) 0 (0.0%) Adverse event 5 (2.5%) 5 (2.5%) 1 (2.7%) Source: Table 14.3.2.2.2 Abbreviations: eCRF = electronic case report forms; ITT = intent-to-treat; MedDRA = Medical Dictionary for Regulatory Activities (version 15.0); N = number of patients. a A Death eCRF was expected to be completed for the blinded phase of the study; however, there was no Death eCRF created for the open label phase of the study. An entry was made for Subject on the Blinded Death eCRF; however, the death occurred during the open label phase of the trial. No other deaths occurring in the open label phase were reported on the death eCRF. This has caused a discrepancy in the number of deaths reported in the death tables in comparison to the treatment discontinuation tables. A by-patient listing of all deaths is presented in Listing 16.2.7.3 and a summary of TEAEs that led to death by SOC and PT is presented in Table 14.3.2.2.1. All deaths occurred and cause of death is summarized for the intent-to-treat (ITT) population in Table 14.3.2.2.2. A summary of TEAEs resulting in death by SOC and PT adjusting for length of treatment-emergent period (events per 100 patient-year of reporting) is presented in Table 14.3.2.2.1.1. Serious TEAEs Serious TEAEs were reported by 38.6%, 30.3%, and 43.2% of patients for the enzalutamide (DB/OLE), bicalutamide (DB only), and crossover from bicalutamide to enzalutamide groups (OLE only), respectively (Table 6). Table 6. FPorepquulaetniotlny Reported (≥2%) Summary of Serious TEAEs by SOC - Safety Enzalutamide 160 mg Bicalutamide Bicalutamide Patients (N = 197) (N = 198) Crossover to Enzalutamide 160 mg (N = 37) SOC Grade 3/4/5 All Grade All Grade All 3/4/5 3/4/5 Number of patients reporting at least 66 (33.5%) 76 (38.6%) 58 (29.3%) 60 (30.3%) 15 (40.5%) 16 (43.2%) 1 serious TEAE Blood and lymphatic 3 (1.5%) 4 (2.0%) 5 (2.5%) 5 (2.5%) 2 (5.4%) 2 (5.4%) system disorders Cardiac disorders 16 (8.1%) 17 (8.6%) 5 (2.5%) 5 (2.5%) 4 (10.8%) 5 (13.5%) Gastrointestinal 11 (5.6%) 12 (6.1%) 4 (2.0%) 5 (2.5%) 3 (8.1%) 3 (8.1%) disordersGeneral disorders and administration site 9 (4.6%) 10 (5.1%) 7 (3.5%) 7 (3.5%) 0 (0.0%) 0 (0.0%) conditionsInfections and 14 (7.1%) 16 (8.1%) 18 (9.1%) 19 (9.6%) 4 (10.8%) 5 (13.5%) infestationsInjury, poisoning, and procedural 12 (6.1%) 14 (7.1%) 5 (2.5%) 5 (2.5%) 3 (8.1%) 4 (10.8%) complicationsInvestigations 1 (0.5%) 1 (0.5%) 0 (0.0%) 1 (0.5%) 2 (5.4%) 2 (5.4%) Metabolism and 6 (3.0%) 6 (3.0%) 6 (3.0%) 6 (3.0%) 2 (5.4) 2 (5.4%) nutrition disorders Musculoskeletal and connective tissue 9 (4.6%) 11 (5.6%) 2 (1.0%) 2 (1.0%) 1 (2.7%) 2 (5.4%) disordersNeoplasms benign, malignant and 14 (7.1%) 18 (9.1%) 7 (3.5%) 9 (4.5%) 0 (0.0%) 0 (0.0%) unspecified (incl cysts and polyps) Nervous system 9 (4.6%) 19 (9.6%) 6 (3.0%) 7 (3.5%) 5 (13.5%) 6 (16.2%) disordersPsychiatric disorders 3 (1.5%) 4 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Renal and urinary 9 (4.6%) 11 (5.6%) 11 (5.6%) 11 (5.6%) 2 (5.4%) 2 (5.4%) disordersRespiratory, thoracic, and mediastinal 4 (2.0%) 5 (2.5%) 7 (3.5%) 7 (3.5%) 1 (2.7%) 1 (2.7%) disordersSource:Table 14.3.2.1.1 Abbreviations: N = number of patients; NCI-CTCAE = National Cancer Institute - Common Terminology Criteria For Adverse Events; SOC = system organ class; TEAE = treatment-emergent adverse event. Serious TEAEs by SOC and PT is summarized in Table 14.3.2.1.1 and Table 14.3.2.1.1.1. A list of serious TEAEs by-patient is presented in Listing 16.2.7.4. Serious TEAEs that led to study drug discontinuation by SOC and PT is summarized in Table 14.3.2.1.4. A summary of serious TEAEs by SOC, PT, and maximum severity is presented in Table 14.3.2.1.2 and a summary of serious TEAEs by by SOC, PT, and strongest relationship to study drug is presented in Table 14.3.2.1.3. Prespecified analyses of TEAEs of interest include fall, hypertension, nonpathological fractures, mental impairment, neutropenia, seizure (convulsions), and noninfectious encephalopathy/delirium and other prespecified events of clinical interest (fatigue, gastrointestinal events, vascular events, major acute cardiovascular events, renal impairment, and hepatic impairment) as defined in the primary CSR. The incidence of TEAEs of interest was higher in the crossover from bicalutamide to enzalutamide group (OLE only) (83.8% [31 patients] and enzalutamide group [DB/OLE]) (78.2% [154 patients]) than in the bicalutamide group (DB only) (65.2% [129 patients]). The commonly reported TEAEs were fatigue (47.7%, 31.8%, and 27.0% for the enzalutamide [DB/OLE], bicalutamide [DB only], and crossover from bicalutamide to enzalutamide groups [OLE only], respectively); select gastrointestinal events (37.1%, 37.9%, and 43.2%, respectively); select vascular events (17.3%, 10.6%, and 5.4%, respectively); hypertension (15.2%, 6.1%, and 16.2%, respectively), and fall (21.3%, 9.6%, and 21.6%, respectively). An overall summary of TEAEs of interest is presented in Table 14.3.1.1.2. Other Significant TEAEs TEAEs where the action recorded on the AE CRF was to discontinue study drug are summarized by SOC and PT in Table 14.3.1.5.1 and by maximum severity in Table 14.3.1.5.2. Overall, 16.2% (32 patients), 13.1% (26 patients), and 24.3% (9 patients) of patients had at least 1 TEAE that led to discontinuation of study drug for the enzalutamide (DB/OLE), bicalutamide (DB only), and crossover from bicalutamide to enzalutamide groups (OLE only), respectively. The most common TEAEs leading to discontinuation were nausea, decreased appetite, and fatigue. TEAEs that were the primary reason for study drug discontinuation are summarized by SOC and PT in Table 14.3.1.5.3. Subject had the reason for treatment discontinuation listed as AE; however, since the AE was fatal, the reason for treatment discontinuation should have been revised to Death (see Errata). The proportions of patients with dose reductions due to TEAEs was 21.6% in the crossover from bicalutamide to enzalutamide group (OLE only), 8.1% in the enzalutamide group (DB/OLE), and 1.5% in the bicalutamide group (DB only), and few were Grade 3 or higher (8.1%, 1.5%, and 1.0%, respectively). TEAEs that led to reduce the dose of study drug are summarized by SOC and PT, and by maximum severity in Table 14.3.1.6.1 and Table 14.3.1.6.2, respectively. The proportion of patients with interruption of dose due to TEAEs was 27.0% in the crossover from bicalutamide to enzalutamide group (OLE only), 23.4% in the enzalutamide group (DB/OLE), and 14.1% in the bicalutamide group (DB only), and there were 17.8%, 11.6%, and 16.2% of patients with a Grade 3 or higher TEAE for the enzalutamide (DB/OLE), bicalutamide (DB only), and crossover from bicalutamide to enzalutamide groups (OLE only), respectively. TEAEs that led to interrupt the dose of study drug are summarized respectively. Variations in incidence of TEAEs may be accounted for by differences in sample size. Other Safety Data Hematological Parameters No patients in the crossover from bicalutamide to enzalutamide (OLE only) group had a post-baseline Grade 3 or 4 hematology laboratory toxicity. The incidence of post-baseline Grade 3 or 4 hematology laboratory toxicities was low (2.5%) in the enzalutamide (DB/OLE) and bicalutamide groups (DB only). All Grade 3 or 4 laboratory values for hematology by-patient is listed in Listing 16.2.8.1.1 and a summary of Grade 3 or 4 laboratory values for hematology is presented in Table 14.3.4.1. Serum Chemistry No patients in the crossover from bicalutamide to enzalutamide group (OLE only) had a post-baseline Grade 3 or 4 serum chemistry laboratory toxicity. Grade 3 or 4 serum chemistry laboratory toxicities occurred in less than 3% of patients except for high glucose: (enzalutamide group [DB/OLE]: 9.1% [18 patients]; bicalutamide group [DB only]: 6.1% [12 patients]) and alkaline phosphatase (only in bicalutamide group [DB only]: 3.5% [7 patients]). All Grade 3 or 4 laboratory values for serum chemistry by-patient is listed in Listing 16.2.8.2.1 and a summary of Grade 3 or 4 serum chemistry laboratory toxicities (post-baseline) are summarized in Table 14.3.4.2. Vital Signs Overall, incidence of abnormal systolic and diastolic blood pressure was higher in the enzalutamide group (DB/OLE) (systolic: 81.2%; diastolic: 40.1%) than in the bicalutamide group (DB only) (systolic: 65.2%; diastolic: 26.8%) and the crossover from bicalutamide to enzalutamide group (OLE only) (systolic: 62.2%; diastolic: 27.0%). The incidence of abnormal heart rate was similar between the treatment groups: 1.5%, 2.5%, and 2.7%, for the enzalutamide, bicalutamide, and crossover from bicalutamide to enzalutamide groups, respectively. Potentially clinically significant changes in vital signs are presented in Table 14.3.5. A list of vital signs by-patients is listed in Listing 16.2.8.3. Death Narratives Full narratives are provided in Section 14.3.3 of the primary CSR for all patients in both treatment groups who died within 30 days of initiation or discontinuation. Additional narratives from the OLE phase have been appended to this report. Other Serious Adverse Event Narratives Full narratives are provided in Section 14.3.3 of the primary CSR for all patients in both treatment groups who experienced a treatment-emergent SAE. Additional narratives from the OLE phase have been appended to this report. Full narratives are provided in Section 14.3.3 of the primary CSR for all patients in both treatment groups who experienced an AE that was the primary reason for discontinuation of study drug or who had a Grade 3 or 4 AST or ALT elevation. Additional narratives from the OLE phase have been appended to this report. CONCLUSION Treatment with enzalutamide was generally well tolerated and safety results were consistent with results from the primary CSR; no new safety signals were identified. The variation in incidence of TEAEs and Serious TEAEs, TEAEs that led to death and discontinuation, study-drug related TEAEs, and TEAEs of interest may be accounted for by the differences in sample size and disease burden at the time of crossover. Patients who crossed over from bicalutamide in the DB phase to enzalutamide in the OLE may have had cancer progression and received alternative treatment in the interim period and therefore may have been more ill or at risk for TEAEs. The safety profiles of enzalutamide and bicalutamide have been well elucidated and are consistent with those observed in this study. NOTE: Since this is a supplemental study report, not all of the tables applicable to a full study report are necessarily included. Therefore, there may be gaps in the sequences of table numbers. The report has been carefully reviewed to ensure that all relevant tables are present. Table 14.1.1 Treatment Compliance and Exposure – Safety Population Table 14.1.2 Table 14.1.3 Table 14.1.4 Safety Data Summary Adverse Events Table 14.3.1.1.1 Overall Summary of Treatment-Emergent Adverse Events – Safety Population Table 14.3.1.1.2 Overall Summary of Treatment-Emergent Adverse Events of Interest – Safety Population Table 14.3.1.2.1 Treatment-Emergent Adverse Events by System Organ Class and Preferred Term – Safety Population Table 14.3.1.2.2 Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Maximum Severity – Safety Population Table 14.3.1.2.3 Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Strongest Relationship to Study Drug – Safety Population Table 14.3.1.2.4 Treatment-Emergent Adverse Events by Decreasing Frequency of Preferred Term – Safety Population Table 14.3.1.2.5 Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Adjusting for Length of Treatment Emergent Period: Events per 100 Patient-Year of Reporting – Safety Population Table 14.3.1.2.6 Treatment-Emergent Adverse Events by System Organ Class and Preferred Term by Treatment Day of Onset: 1 - 30 Days, 1 - 180 Days, 1 - 365 Days, and Total – Safety Population Table 14.3.1.3.1 Grade 3 or Higher Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term – Safety Population Table 14.3.1.3.2 Grade 3 or Higher Treatment-Emergent Adverse Events by Decreasing Frequency of Preferred Term – Safety Population Table 14.3.1.3.3 Grade 3 or Higher Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Strongest Relationship to Study Drug – Safety Population Table 14.3.1.3.4 Grade 3 or Higher Treatment-Emergent Adverse Events by System Organ Class and Preferred Term by Treatment Day of Onset Cut Point: 1 - 30 Days, 1 - 180 Days, 1 - 365 Days, and Total – Safety Population Table 14.3.1.4.1 Study Drug-Related Treatment-Emergent Adverse Events by System Organ Class and Preferred Term – Safety Population Table 14.3.1.4.2 Study Drug-Related Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Maximum Severity – Safety Population Table 14.3.1.5.1 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation by System Organ Class and Preferred Term – Safety Population Table 14.3.1.5.2 Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation by System Organ Class, Preferred Term, and Maximum Severity – Safety Population Table 14.3.1.5.3 Treatment-Emergent Adverse Events That Were Primary Reason for Study Drug Discontinuation by System Organ Class and Preferred Term – Safety Population Table 14.3.1.6.1 Treatment-Emergent Adverse Events Leading to Dose Reduction of Study Drug by System Organ Class and Preferred Term – Safety Population Table 14.3.1.6.2 Treatment-Emergent Adverse Events Leading to Dose Reduction of Study Drug by System Organ Class, Preferred Term, and Maximum Severity – Safety Population System Organ Class and Preferred Term – Safety Population Table 14.3.1.7.2 Treatment-Emergent Adverse Events Leading to Dose Interruption of Study Drug System Organ Class, Preferred Term, and Maximum Severity – Safety Population Listings of Deaths, Other Serious and Significant Adverse Events Table 14.3.2.1.1 Serious Treatment-Emergent Adverse Events by System Organ Class and Preferred Term – Safety Population Table 14.3.2.1.1.1 Serious Treatment-Emergent Adverse Events by Decreasing Frequency of Preferred Term – Safety Population Table 14.3.2.1.2 Serious Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Maximum Severity – Safety Population Table 14.3.2.1.3 Serious Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Strongest Relationship to Study Drug – Safety Population Table 14.3.2.1.4 Serious Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation by System Organ Class and Preferred Term – Safety Population Table 14.3.2.1.5 Serious Treatment-Emergent Adverse Events by System Organ Class and Preferred Term by Treatment Day of Onset Cut Point: 1 - 30 Days, 1 - 180 Days, 1 - 365 Days, and Total – Safety Population Table 14.3.2.2.1 Treatment-Emergent Adverse Events Leading to Death by System Organ Class and Preferred Term – Safety Population Table 14.3.2.2.1.1 Treatment-Emergent Adverse Events Resulting in Death by System Organ Class and Preferred Term Adjusting for Length of Treatment Emergent Period: Events per 100 Patient-Year of Reporting – Safety Population Table 14.3.2.2.2 Summary of All Deaths – ITT Population Narratives of Deaths, Other Serious, and Certain Other Significant Adverse Events Table 14.3.3 Narratives From OLE Phase 14.3.3.1 Death Narratives 14.3.3.2 All Other Serious Adverse Event Narratives Abnormal Laboratory Value Listings Table 14.3.4.1 Hematology Results: Summary of Grade 3 and 4 Postbaseline Laboratory Toxicities – Safety Population Table 14.3.4.2 Chemistry Results: Summary of Grade 3 and 4 Postbaseline Laboratory Toxicities – Safety Population Vital Signs Table 14.3.5 Potentially Clinically Significant Changes in Vital Signs – Safety Population REFERENCES (NOT APPLICABLE) 